LH

Laboratory
D

LH

Arincen56/100B
366.71
USD
3.41
(0.94%)
Post Trading·366.57USD-0.14(-0.04%)
Fair value489.00Plus-25%367Price 366.71611
Q4 FY2026 · Earnings report
EPS estimate 4.50Revenue estimate 3.75B
OverviewFinancialsForecastEarningsDividendsCompany

Laboratory net income 1988–2026

Laboratory earned 262.80M USD in Q3 FY2026, the three months to 30 September 2026, up 0.7% on the same quarter a year before. Laboratory's net income over the last twelve months was 1.00B USD, up 17.4% on the twelve months before. In fiscal year 2025 it earned 876.50M USD, up 17.5% on the year before.

Last updated 6 Nov 2026 · Next report 16 Feb 2027

Net income

Net income · +7.2% a year over 10 yearsNet margin

Growth

Fiscal yearPeriod endingNet incomeGrowthNet marginRevenue
TTM30 Sept 20261.00B+17.40%6.88%14.59B
FY202531 Dec 2025876.50M+17.49%6.28%13.95B
FY202431 Dec 2024746.00M+78.47%5.73%13.01B
FY202331 Dec 2023418.00M-67.32%3.44%12.16B
FY202231 Dec 20221.28B-46.20%10.78%11.86B
FY202131 Dec 20212.38B+52.77%18.10%13.14B
FY202031 Dec 20201.56B+88.89%11.13%13.98B
FY201931 Dec 2019823.80M-6.78%7.13%11.55B
FY201831 Dec 2018883.70M-30.32%7.80%11.33B
FY201731 Dec 20171.27B+73.23%12.15%10.44B
FY201631 Dec 2016732.10M+67.57%7.59%9.64B
FY201531 Dec 2015436.90M-14.53%5.03%8.68B
FY201431 Dec 2014511.20M-10.91%8.50%6.01B
FY201331 Dec 2013573.80M-1.59%9.88%5.81B
FY201231 Dec 2012583.10M+12.20%10.28%5.67B
FY201131 Dec 2011519.70M-6.90%9.38%5.54B
FY201031 Dec 2010558.20M+2.74%11.16%5.00B
FY200931 Dec 2009543.30M+16.96%11.57%4.69B
FY200831 Dec 2008464.50M-2.58%10.31%4.51B
FY200731 Dec 2007476.80M+10.47%11.72%4.07B
FY200631 Dec 2006431.60M+11.76%12.02%3.59B
FY200531 Dec 2005386.20M+6.39%11.61%3.33B
FY200431 Dec 2004363.00M+13.08%11.77%3.08B
FY200331 Dec 2003321.00M+26.08%10.92%2.94B
FY200231 Dec 2002254.60M+41.84%10.15%2.51B
FY200131 Dec 2001179.50M+60.12%8.16%2.20B
FY200031 Dec 2000112.10M+71.41%5.84%1.92B
FY199931 Dec 199965.40M-4.94%3.85%1.70B
FY199831 Dec 199868.80M—4.27%1.61B
FY199731 Dec 1997-106.90M—-7.04%1.52B
FY199631 Dec 1996-153.50M—-9.55%1.61B
FY199531 Dec 1995-12.30M-140.86%-0.86%1.43B
FY199431 Dec 199430.10M-73.29%3.45%872.50M
FY199331 Dec 1993112.70M+177.59%14.82%760.50M
FY199231 Dec 199240.60M-60.92%5.63%721.40M
FY199131 Dec 1991103.90M+25.79%17.20%603.90M
FY199031 Dec 199082.60M+27.67%16.46%501.90M
FY198931 Dec 198964.70M+31.77%16.08%402.40M
FY198831 Dec 198849.10M—15.64%313.90M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Laboratory's profit

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.